179 related articles for article (PubMed ID: 26207639)
1. Reasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort Analysis.
Sun J; Liu L; Shen J; Qi T; Wang Z; Song W; Zhang R; Lu H
PLoS One; 2015; 10(7):e0133242. PubMed ID: 26207639
[TBL] [Abstract][Full Text] [Related]
2. Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa.
Onoya D; Hirasen K; van den Berg L; Miot J; Long LC; Fox MP
Drug Saf; 2018 Dec; 41(12):1343-1353. PubMed ID: 30043384
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
4. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort.
Rokx C; Fibriani A; van de Vijver D; Verbon A; Schutten M; Gras L; Rijnders BJ
J Int AIDS Soc; 2014; 17(4 Suppl 3):19491. PubMed ID: 25394000
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with the first antiretroviral therapy modification in older HIV-1 positive patients.
Kowalska JD; Kubicka J; Siwak E; Pulik P; Firląg-Burkacka E; Horban A;
AIDS Res Ther; 2016; 13():2. PubMed ID: 26744599
[TBL] [Abstract][Full Text] [Related]
6. Patterns and Predictors of First-Line Antiretroviral Therapy Modification in HIV-1-Infected Adults in a Large Urban Outpatient Cohort in Nigeria.
Abah IO; Darin KM; Ebonyi AO; Ugoagwu P; Ojeh VB; Nasir N; Falang KD; Olaitan O; Agbaji O; Idoko J; Kanki P
J Int Assoc Provid AIDS Care; 2015; 14(4):348-54. PubMed ID: 25566781
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral therapy regimen modification rates and associated factors in a cohort of HIV/AIDS patients in Asmara, Eritrea: a 16-year retrospective analysis.
Mengistu ST; Yohannes A; Issaias H; Mesfn M; Zerufael S; Dirar A; Teklemariam HM; Ghebremeskel GG; Achila OO; Basha S
Sci Rep; 2023 Mar; 13(1):4183. PubMed ID: 36918596
[TBL] [Abstract][Full Text] [Related]
8. Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
Inzaule S; Otieno J; Kalyango J; Nafisa L; Kabugo C; Nalusiba J; Kwaro D; Zeh C; Karamagi C
PLoS One; 2014; 9(4):e93106. PubMed ID: 24695108
[TBL] [Abstract][Full Text] [Related]
9. Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010.
Jarrin I; Hernández-Novoa B; Alejos B; Riera M; Navarro G; Bernardino JI; Rivero M; del Amo J; Moreno S;
Antivir Ther; 2013; 18(2):161-70. PubMed ID: 22997147
[TBL] [Abstract][Full Text] [Related]
10. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
12. Predictors of adverse drug reaction among adult HIV-infected patients on antiretroviral therapy in government hospitals of Kaffa Zone, Ethiopia; November 2018: a retrospective cohort.
Mitkie AA; Bekele FB; Debiso AT
Pan Afr Med J; 2021; 38():181. PubMed ID: 33995787
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes of initial differential antiretroviral regimens among HIV patients in Southwest China: comparison from an observational cohort study.
Kang R; Luo L; Chen H; Zhu Q; Liao L; Xing H; Zhu J; Shen Z; Lan G; Tang Z; Shao Y; Yang W; Ruan Y
BMJ Open; 2019 Mar; 9(3):e025666. PubMed ID: 30928945
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort.
Fusco P; Nasta P; Quiros-Roldan E; Tondinelli A; Costa C; Fornabaio C; Mazzini N; Prosperi M; Torti C; Carosi G
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112904
[No Abstract] [Full Text] [Related]
15. Rate of initial highly active anti-retroviral therapy regimen change and its predictors among adult HIV patients at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow up study.
Anlay DZ; Alemayehu ZA; Dachew BA
AIDS Res Ther; 2016; 13():10. PubMed ID: 26889204
[TBL] [Abstract][Full Text] [Related]
16. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
17. Multi-state Markov model for time to treatment changes for HIV/AIDS patients: a retrospective cohort national datasets, Ethiopia.
Kumsa TH; Mulu A; Beyene J; Asfaw ZG
BMC Infect Dis; 2024 Jun; 24(1):627. PubMed ID: 38914968
[TBL] [Abstract][Full Text] [Related]
18. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
Jarrin I; Hernández-Novoa B; Alejos B; Santos I; Lopez-Aldeguer J; Riera M; Gutiérrez F; Rubio R; Antela A; Blanco JR; Moreno S;
HIV Med; 2014 Oct; 15(9):547-56. PubMed ID: 24655804
[TBL] [Abstract][Full Text] [Related]
19. Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study.
Ayele T; Jarso H; Mamo G
AIDS Res Ther; 2017 Feb; 14(1):5. PubMed ID: 28143541
[TBL] [Abstract][Full Text] [Related]
20. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
Kumarasamy N; Vallabhaneni S; Cecelia AJ; Yepthomi T; Balakrishnan P; Saghayam S; Flanigan TP; Carpenter CC; Solomon S; Mayer KH
J Acquir Immune Defic Syndr; 2006 Jan; 41(1):53-8. PubMed ID: 16340473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
